Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9119, USA.
CNS Drugs. 2010 Apr;24(4):267-84. doi: 10.2165/11530230-000000000-00000.
Depression is associated with significant functional impairment and reduced quality of life. Disruptions occur both globally as well as in specific functional areas such as work, interpersonal relationships and cognitive function. From both a clinical and research perspective, much focus has been given to the resolution of symptoms associated with depression, while relatively little attention has been given to functional improvements. Definitions of remission in depression are most frequently based on achieving a cut-off score on clinical rating scales of depressive symptoms. Research in this area has sparsely included psychosocial function or health-related quality of life as a primary outcome measure in clinical trials. However, the need to fully understand the impact of depression and its treatments on functioning is great, given the existing evidence of the profound effect that depression has on function. Even mild depressive symptoms and subsyndromal depression result in functional impairment and reduced quality of life, and untreated residual depressive symptomatology can result in an increased likelihood for relapse of the fully symptomatic disorder (i.e. major depressive disorder). Therefore, clinicians and researchers alike need to broaden the focus of treatment to encompass not only the specific symptoms of depression, but the functional consequences as well. Many tools have been developed to assess function and quality of life, both globally as well as within specific domains. In addition, the effect of residual symptoms associated with functional impairment (i.e. insomnia, fatigue, pain [somatic] symptoms and cognition) in depression, even independently of depressive symptoms, warrants evaluation and monitoring. Recommendations for evaluating functional outcomes include: (i) adequately assessing functional impairment; (ii) identifying and/or developing treatment plans that will target symptoms associated with functional impairments; and (iii) monitoring functional impairments and associated symptoms throughout the course of treatment. The development of treatments that specifically target improvements in functional impairments is needed, and may require the use of novel treatment strategies.
抑郁症与显著的功能障碍和生活质量下降有关。这种障碍不仅会在整体上出现,还会出现在特定的功能领域,如工作、人际关系和认知功能。无论是从临床还是研究的角度来看,人们都非常关注与抑郁症相关症状的缓解,而相对较少关注功能的改善。抑郁症缓解的定义通常基于临床抑郁症状评定量表的得分达到临界值。在这一领域的研究中,很少将心理社会功能或健康相关生活质量作为临床试验的主要结局指标。然而,鉴于抑郁症对功能的影响如此深远,充分了解抑郁症及其治疗对功能的影响非常重要。即使是轻度抑郁症状和亚综合征抑郁也会导致功能障碍和生活质量下降,未治疗的残留抑郁症状可能会增加完全有症状的疾病(即重度抑郁症)复发的可能性。因此,临床医生和研究人员都需要扩大治疗重点,不仅要包括抑郁的具体症状,还要包括功能后果。已经开发出许多工具来评估功能和生活质量,无论是整体评估还是特定领域评估。此外,与功能障碍相关的残留症状(即失眠、疲劳、疼痛[躯体]症状和认知)对抑郁症的影响,即使独立于抑郁症状,也值得评估和监测。评估功能结果的建议包括:(i)充分评估功能障碍;(ii)确定和/或制定将针对与功能障碍相关的症状的治疗计划;(iii)在整个治疗过程中监测功能障碍和相关症状。需要开发专门针对功能障碍改善的治疗方法,可能需要使用新的治疗策略。